We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Is the Induction of Insulin Production in Gut Stem Cells a Possible Treatment for Diabetes?

By LabMedica International staff writers
Posted on 19 Mar 2012
Abolishing the activity of the Foxo1 gene in mouse gut Neurog3+ progenitor cells caused these cells to differentiate into a type capable of producing fully active insulin.

Stem cell therapy to replace insulin producing pancreatic beta cells has been considered for treatment of type I diabetes. More...
However, such cells would not be under hormonal control and could produce dangerously high levels of insulin.

Another approach is to induce other types of normally occurring cells to manufacture the hormone. Investigators at Columbia University (New York, NY, USA) inadvertently revealed the potential of this technique when they used genetic engineering to abolish the activity of the mouse Foxo1gene in gut stem cells known as Neurog3+ progenitor cells.

The investigators reported in the March 11, 2012, issue of the journal Nature Genetics that Neurog3+ progenitors actually require active Foxo1 to prevent differentiation into insulin producing cells. Without Foxo1 the gut cells produced insulin that was released into the bloodstream where it worked as well as normal insulin. The gut cells produced insulin in sufficient quantity to nearly normalize blood glucose levels in otherwise diabetic mice.

“Our results show that it could be possible to regrow insulin-producing cells in the GI tracts of our pediatric and adult patients,” said senior author Dr. Domenico Accili, professor of medicine at Columbia University. “Nobody would have predicted this result. Many things could have happened after we knocked out Foxo1. In the pancreas, when we knock out Foxo1, nothing happens. So why does something happen in the gut? Why do we not get a cell that produces some other hormone? We do not yet know.”

“All these findings make us think that coaxing a patient's gut to make insulin-producing cells would be a better way to treat diabetes than therapies based on embryonic or induced pluripotent stem cells,” said Dr. Accili. “However, it is important to realize that a new treatment for type I diabetes needs to be just as safe as, and more effective than, insulin. We cannot test treatments that are risky just to remove the burden of daily injections. Insulin is not simple or perfect, but it works and it is safe.”

Related Links:

Columbia University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.